A detailed history of Rovin Capital transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Rovin Capital holds 12,870 shares of BMY stock, worth $697,296. This represents 0.22% of its overall portfolio holdings.

Number of Shares
12,870
Previous 5,324 141.74%
Holding current value
$697,296
Previous $289,000 84.78%
% of portfolio
0.22%
Previous 0.12%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 18, 2024

BUY
$40.25 - $52.99 $303,726 - $399,862
7,546 Added 141.74%
12,870 $534,000
Q1 2024

Apr 22, 2024

BUY
$47.98 - $54.4 $255,445 - $289,625
5,324 New
5,324 $289,000
Q1 2023

Apr 05, 2023

SELL
$65.71 - $74.53 $1,117 - $1,267
-17 Reduced 0.57%
2,945 $204,000
Q4 2022

Jan 23, 2023

SELL
$68.48 - $81.09 $3,150 - $3,730
-46 Reduced 1.53%
2,962 $213,000
Q3 2022

Oct 25, 2022

SELL
$0.13 - $76.84 $14 - $8,375
-109 Reduced 3.5%
3,008 $214,000
Q2 2022

Jul 22, 2022

SELL
$72.62 - $79.98 $327,734 - $360,949
-4,513 Reduced 59.15%
3,117 $240,000
Q1 2022

Jun 13, 2022

SELL
$61.48 - $73.72 $240,079 - $287,876
-3,905 Reduced 33.85%
7,630 $557,000
Q4 2021

Feb 24, 2022

BUY
$53.63 - $62.52 $618,622 - $721,168
11,535 New
11,535 $719,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $115B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Rovin Capital Portfolio

Follow Rovin Capital and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rovin Capital , based on Form 13F filings with the SEC.

News

Stay updated on Rovin Capital with notifications on news.